Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:44 am
Author: Getaka|Social: XLinkedIn

Sun Pharmaceuticals Industries Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹1,512.06Overvalued by 12.50%vs CMP ₹1,728.00

P/E (34.2) × ROE (16.9%) × BV (₹324.00) × DY (0.93%)

₹878.55Overvalued by 49.16%vs CMP ₹1,728.00
MoS: -96.7% (Negative)Confidence: 63/100 (Moderate)Models: 1 Under, 8 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹1,924.0123%Under (+11.3%)
Graham NumberEarnings₹575.9317%Over (-66.7%)
Earnings PowerEarnings₹313.4411%Over (-81.9%)
DCFCash Flow₹1,097.9411%Over (-36.5%)
Net Asset ValueAssets₹324.257%Over (-81.2%)
EV/EBITDAEnterprise₹715.309%Over (-58.6%)
Earnings YieldEarnings₹455.007%Over (-73.7%)
ROCE CapitalReturns₹405.377%Over (-76.5%)
Revenue MultipleRevenue₹328.616%Over (-81%)
Consensus (9 models)₹878.55100%Overvalued
Key Drivers: EPS CAGR 27.2% lifts DCF — verify sustainability. | Wide model spread (₹313–₹1,924) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 27.2%

*Investments are subject to market risks

Investment Snapshot

65
Sun Pharmaceuticals Industries Ltd scores 65/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health87/100 · Strong
ROCE 20.2% ExcellentROE 16.9% GoodD/E 0.07 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money45/100 · Moderate
FII holding down -1.84% (6mo) SellingDII holding up 2.14% MF buyingPromoter holding at 54.5% Stable
Earnings Quality50/100 · Moderate
OPM stable around 28% Steady
Quarterly Momentum50/100 · Moderate
Revenue (4Q): +10% YoY GrowingProfit (4Q): -5% YoY Declining
Industry Rank80/100 · Strong
P/E 34.2 vs industry 53.8 Cheaper than peersROCE 20.2% vs industry 16.4% Above peers3Y sales CAGR: 11% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:44 am

Market Cap 4,14,725 Cr.
Current Price 1,728
Intrinsic Value₹878.55
High / Low 1,851/1,547
Stock P/E34.2
Book Value 324
Dividend Yield0.93 %
ROCE20.2 %
ROE16.9 %
Face Value 1.00
PEG Ratio1.26

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Sun Pharmaceuticals Industries Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Sun Pharmaceuticals Industries Ltd 4,14,725 Cr. 1,728 1,851/1,54734.2 3240.93 %20.2 %16.9 % 1.00
Torrent Pharmaceuticals Ltd 1,39,145 Cr. 4,111 4,483/3,10160.4 2500.78 %27.0 %26.5 % 5.00
Lupin Ltd 1,04,004 Cr. 2,275 2,378/1,77420.9 4300.53 %21.3 %20.6 % 2.00
Dr Reddys Laboratories Ltd 1,00,960 Cr. 1,210 1,380/1,02018.1 4320.66 %22.7 %18.0 % 1.00
Cipla Ltd 96,603 Cr. 1,196 1,673/1,19420.3 4081.09 %22.7 %17.8 % 2.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Sun Pharmaceuticals Industries Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 11,24110,93111,94112,19212,38111,98312,65313,29113,67512,95913,85114,47815,521
Expenses 8,2378,1298,6099,0138,9048,9489,0459,3529,6669,2439,5509,95110,572
Operating Profit 3,0042,8023,3323,1793,4773,0353,6083,9394,0093,7164,3024,5274,948
OPM % 27%26%28%26%28%25%29%30%29%29%31%31%32%
Other Income 174202-118294180504533354149251-35447089
Interest 469381493574626952497510078
Depreciation 660672651633622650655626631664701730732
Profit before tax 2,4712,2402,4812,7913,0002,8163,4243,5983,4763,2543,1734,1684,227
Tax % 11%10%19%14%14%5%16%16%16%34%27%25%20%
Net Profit 2,1811,9832,0062,3852,5612,6592,8613,0372,9132,1542,2933,1253,381
EPS in Rs 9.038.278.439.9010.5211.0611.8212.6712.108.969.5013.0014.04

Last Updated: February 4, 2026, 1:16 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 12:16 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 16,08027,39228,48731,57826,48929,06632,83833,49838,65443,88648,49752,57856,809
Expenses 9,07819,49820,31321,47620,85822,68925,85525,02828,39732,23535,47937,46439,316
Operating Profit 7,0037,8948,17410,1025,6316,3776,9838,47010,25811,65013,01815,11417,493
OPM % 44%29%29%32%21%22%21%25%27%27%27%29%31%
Other Income -1,968283-42610-135-258382-3,449-3,5054598651,444457
Interest 44579523400518555303141127172238231302
Depreciation 4091,1951,0381,2651,5001,7532,0532,0802,1442,5292,5572,5752,826
Profit before tax 4,5816,4036,5719,0483,4793,8105,0102,7994,4819,40811,08813,75214,822
Tax % 15%14%14%13%26%16%16%18%24%9%13%20%
Net Profit 3,8795,4765,6587,8462,5423,2084,1722,2723,3898,5139,61010,96510,953
EPS in Rs 15.1721.9218.8929.038.7311.1115.6912.1013.6435.3239.9145.5545.50
Dividend Payout % 10%14%5%12%23%25%25%62%73%33%34%35%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)41.17%3.32%38.67%-67.60%26.20%30.05%-45.54%49.16%151.20%12.89%14.10%
Change in YoY Net Profit Growth (%)0.00%-37.85%35.35%-106.27%93.80%3.85%-75.59%94.71%102.03%-138.31%1.21%

Sun Pharmaceuticals Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:7%
5 Years:10%
3 Years:11%
TTM:9%
Compounded Profit Growth
10 Years:10%
5 Years:24%
3 Years:20%
TTM:9%
Stock Price CAGR
10 Years:6%
5 Years:25%
3 Years:21%
1 Year:-13%
Return on Equity
10 Years:14%
5 Years:16%
3 Years:17%
Last Year:17%

Last Updated: September 5, 2025, 1:36 pm

Balance Sheet

Last Updated: December 4, 2025, 2:02 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 207207241240240240240240240240240240240
Reserves 18,31825,43132,74236,40038,07441,16945,02546,22347,77155,75563,42771,97877,580
Borrowings 2,5618,9968,4979,83210,38510,5148,3153,8691,2906,8863,2742,3625,215
Other Liabilities 8,00914,08913,94814,62415,59812,66614,61517,29120,47417,83118,38717,32820,672
Total Liabilities 29,09548,72355,42861,09564,29764,59068,19467,62269,77680,71285,32891,908103,706
Fixed Assets 6,81712,68215,87217,67518,85321,83722,84721,55322,66524,06523,24822,58633,371
CWIP 8422,0392,1752,8012,4651,4111,2201,5671,2874,9735,3546,6441,355
Investments 2,7862,7161,8301,1927,1437,90310,1439,61212,84914,82415,02618,35419,543
Other Assets 18,65031,28635,55039,42735,83733,43933,98434,89032,97536,84941,70044,32449,438
Total Assets 29,09548,72355,42861,09564,29764,59068,19467,62269,77680,71285,32891,908103,706

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 3,9595,6166,6867,0823,9072,1966,5556,1708,9854,95912,13514,072
Cash from Investing Activity + -2,176-1,502-3,949-4,186-3,104-310-2,225407-5,556-7,220-763-5,183
Cash from Financing Activity + 507-1,187-1,889-2,285-1,539-2,731-5,715-5,980-5,1932,376-6,710-7,906
Net Cash Flow 2,2902,927848611-736-844-1,386596-1,7651154,662983
Free Cash Flow 3,0623,3163,3533,4922,013-9665,1055,0977,5502,8959,96412,005
CFO/OP 68%93%106%90%83%48%113%85%78%56%105%96%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow5.00-1.000.001.00-5.00-4.00-2.005.009.005.0010.0013.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 506887831081121059999958591
Inventory Days 410307370307338366311378315360338348
Days Payable 174178207197234192142167158194194210
Cash Conversion Cycle 286197251193212285274310255261229228
Working Capital Days 71-737-4-3131515147405565
ROCE %34%23%18%20%10%10%10%13%17%16%17%20%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%54.48%
FIIs 16.88%16.48%16.78%17.08%17.72%17.23%18.01%18.04%17.96%17.26%16.55%16.12%
DIIs 19.18%19.65%19.56%19.42%18.71%19.17%18.48%18.43%18.58%19.38%20.12%20.72%
Government 0.06%0.09%0.10%0.11%0.11%0.11%0.11%0.11%0.11%0.11%0.11%0.11%
Public 9.38%9.28%9.05%8.92%8.97%9.00%8.89%8.92%8.86%8.76%8.72%8.57%
No. of Shareholders 6,25,2526,24,5616,16,5886,12,6266,31,3926,73,2176,57,3176,89,6237,04,9837,23,7707,43,8777,10,900

Shareholding Pattern Chart

No. of Shareholders

Sun Pharmaceuticals Industries Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
ICICI Prudential Value Fund 15,466,098 4.44 2686.4618,077,4482026-03-23 10:36:30-14.45%
ICICI Prudential Equity & Debt Fund 12,144,223 4.2 2109.4514,178,0732026-03-23 10:36:30-14.35%
ICICI Prudential Large Cap Fund 11,153,571 2.5 1937.3812,103,8842026-03-23 10:36:30-7.85%
HDFC Balanced Advantage Fund 8,346,339 1.35 1449.767,414,8892026-02-23 04:02:0312.56%
ICICI Prudential India Opportunities Fund 6,827,584 3.33 1185.957,527,5842026-03-24 00:22:07-9.3%
Nippon India Pharma Fund 6,256,349 13.08 1086.736,556,3492025-12-08 04:19:42-4.58%
ICICI Prudential Multi Asset Fund 5,931,574 1.24 1030.315,960,9372026-02-23 04:02:03-0.49%
ICICI Prudential ELSS Tax Saver Fund 5,292,223 6.4 919.265,105,9692026-02-23 04:02:033.65%
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund 4,389,473 11.21 762.454,673,5602026-03-23 10:36:30-6.08%
ICICI Prudential Balanced Advantage Fund 3,745,554 0.91 650.64,827,0542026-03-23 10:36:30-22.4%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 45.6039.9035.3013.6012.10
Diluted EPS (Rs.) 45.6039.9035.3013.6012.10
Cash EPS (Rs.) 56.5050.8746.2223.1318.19
Book Value[Excl.RevalReserv]/Share (Rs.) 301.00265.36247.22212.84206.23
Book Value[Incl.RevalReserv]/Share (Rs.) 301.00265.36247.22212.84206.23
Revenue From Operations / Share (Rs.) 219.14202.13182.91161.11139.62
PBDIT / Share (Rs.) 71.8459.9251.1947.1838.87
PBIT / Share (Rs.) 61.1149.2740.6438.2430.20
PBT / Share (Rs.) 57.3246.2139.2118.6811.67
Net Profit / Share (Rs.) 45.7640.2135.6814.209.52
NP After MI And SOA / Share (Rs.) 45.5539.9135.3213.6412.10
PBDIT Margin (%) 32.7829.6427.9829.2827.84
PBIT Margin (%) 27.8824.3722.2223.7321.63
PBT Margin (%) 26.1522.8621.4311.598.35
Net Profit Margin (%) 20.8819.8919.508.816.82
NP After MI And SOA Margin (%) 20.7819.7419.308.468.66
Return on Networth / Equity (%) 15.1315.0415.136.816.24
Return on Capital Employeed (%) 19.8317.2616.0217.4414.06
Return On Assets (%) 11.8611.2010.494.684.29
Long Term Debt / Equity (X) 0.000.000.000.000.01
Total Debt / Equity (X) 0.020.040.110.010.07
Asset Turnover Ratio (%) 0.590.580.580.560.49
Current Ratio (X) 2.892.562.002.041.89
Quick Ratio (X) 2.331.981.481.511.33
Inventory Turnover Ratio (X) 5.234.760.790.780.72
Dividend Payout Ratio (NP) (%) 33.0630.2629.7365.9653.68
Dividend Payout Ratio (CP) (%) 26.7623.8822.8939.8531.28
Earning Retention Ratio (%) 66.9469.7470.2734.0446.32
Cash Earning Retention Ratio (%) 73.2476.1277.1160.1568.72
Interest Coverage Ratio (X) 74.5060.2971.4088.8865.95
Interest Coverage Ratio (Post Tax) (X) 51.3943.5351.7763.6047.60
Enterprise Value (Cr.) 407192.46384570.80239622.86218440.19143296.74
EV / Net Operating Revenue (X) 7.747.935.465.654.28
EV / EBITDA (X) 23.6226.7519.5119.3015.36
MarketCap / Net Operating Revenue (X) 7.928.025.375.684.28
Retention Ratios (%) 66.9369.7370.2634.0346.31
Price / BV (X) 5.776.114.214.573.09
Price / Net Operating Revenue (X) 7.928.025.375.684.28
EarningsYield 0.020.020.030.010.02

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Sun Pharmaceutical Industries Ltd. is a Public Limited Listed company incorporated on 01/03/1993 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1993PLC019050 and registration number is 019050. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 23003.33 Cr. and Equity Capital is Rs. 239.93 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsSun Pharma Advanced Research Centre (SPARC), Tandalja, Vadodra Gujarat 390012Contact not found
Management
NamePosition Held
Mr. Dilip S ShanghviChairman & Managing Director
Mr. Aalok D ShanghviWhole Time Director & COO
Ms. Vidhi D ShanghviWhole Time Director
Mr. Sudhir V ValiaNon Exe.Non Ind.Director
Dr. Pawan GoenkaLead Independent Director
Mr. Rama BijapurkarIndependent Director
Mr. Gautam DoshiIndependent Director
Mr. Rolf HoffmannIndependent Director

FAQ

What is the intrinsic value of Sun Pharmaceuticals Industries Ltd and is it undervalued?

As of 09 April 2026, Sun Pharmaceuticals Industries Ltd's intrinsic value is ₹878.55, which is 49.16% lower than the current market price of ₹1,728.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (16.9 %), book value (₹324), dividend yield (0.93 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Sun Pharmaceuticals Industries Ltd?

Sun Pharmaceuticals Industries Ltd is trading at ₹1,728.00 as of 09 April 2026, with a FY2026-2027 high of ₹1,851 and low of ₹1,547. The stock is currently in the middle of its 52-week range. Market cap stands at ₹4,14,725 Cr..

How does Sun Pharmaceuticals Industries Ltd's P/E ratio compare to its industry?

Sun Pharmaceuticals Industries Ltd has a P/E ratio of 34.2, which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Sun Pharmaceuticals Industries Ltd financially healthy?

Key indicators for Sun Pharmaceuticals Industries Ltd: ROCE of 20.2 % indicates efficient capital utilization; ROE of 16.9 % shows strong shareholder returns. Dividend yield is 0.93 %.

Is Sun Pharmaceuticals Industries Ltd profitable and how is the profit trend?

Sun Pharmaceuticals Industries Ltd reported a net profit of ₹10,965 Cr in Mar 2025 on revenue of ₹52,578 Cr. Compared to ₹3,389 Cr in Mar 2022, the net profit shows an improving trend.

Does Sun Pharmaceuticals Industries Ltd pay dividends?

Sun Pharmaceuticals Industries Ltd has a dividend yield of 0.93 % at the current price of ₹1,728.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Sun Pharmaceuticals Industries Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports